Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Investing Activities (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Cash from Investing Activities for 5 consecutive years, with -$1.0 as the latest value for Q3 2019.

  • On a quarterly basis, Cash from Investing Activities rose 100.0% to -$1.0 in Q3 2019 year-over-year; TTM through Sep 2019 was -$437307.0, a 84.28% increase, with the full-year FY2020 number at -$900000.0, down 105.81% from a year prior.
  • Cash from Investing Activities was -$1.0 for Q3 2019 at Outlook Therapeutics, up from -$150737.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $46949.0 in Q1 2016 to a low of -$3.5 million in Q2 2015.
  • A 5-year average of -$632910.3 and a median of -$202226.5 in 2018 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 5165.95% in 2018, then skyrocketed 100.0% in 2019.
  • Outlook Therapeutics' Cash from Investing Activities stood at -$364242.0 in 2015, then soared by 59.27% to -$148362.0 in 2016, then crashed by 624.68% to -$1.1 million in 2017, then skyrocketed by 78.01% to -$236433.0 in 2018, then skyrocketed by 100.0% to -$1.0 in 2019.
  • Per Business Quant, the three most recent readings for OTLK's Cash from Investing Activities are -$1.0 (Q3 2019), -$150737.0 (Q2 2019), and -$50136.0 (Q1 2019).